Agios Pharmaceuticals AGIO Net realized gains (losses)
Net realized gains (losses) at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RealizedInvestmentGainsLosses.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's net realized gains (losses).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's net realized gains (losses)?
- Agios Pharmaceuticals (AGIO) reported net realized gains (losses) of $28K in Q1 2026.
- How has Agios Pharmaceuticals's net realized gains (losses) changed year-over-year?
- Agios Pharmaceuticals's net realized gains (losses) increased by 1300.0% year-over-year, from $2K to $28K.
- What is the long-term trend for Agios Pharmaceuticals's net realized gains (losses)?
- Over 2 years (2023 to 2025), Agios Pharmaceuticals's net realized gains (losses) has grown at a 105.3% compound annual growth rate (CAGR), from $28K to $118K.
- What does net realized gains (losses) mean?
- This captures the actual cash gains or losses recognized upon the sale or maturity of investment securities. It serves as a measure of the performance of the company's treasury management and its ability to generate returns on excess cash reserves. Unlike unrealized gains, this reflects realized financial outcomes that directly impact the company's cash position.